Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPN | P05981 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.37 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8054098 | 0.77 | KMT2A (0.44) | ACHEHTR2CKMT2AMEN1HTR2A | |
| SCHEMBL13818128 | 0.77 | HTR2C (0.47) | ACHEHTR2CKMT2AMEN1HTR2A | |
| SCHEMBL9946122 | 0.75 | KMT2A (0.44) | ACHEHTR2CKMT2AMEN1HTR2A | |
| SCHEMBL2469369 | 0.74 | TAAR1 (0.42) | HTR2CKMT2AMEN1HTR2AHTR2B | |
| SCHEMBL921104 | 0.74 | ALDH1A1 (0.46) | ACHEHTR2CKMT2AMEN1HTR2A | |
| SCHEMBL264648 | 0.74 | KDM1A (0.47) | HTR2CKMT2AMEN1HTR2AHTR2B | |
| SCHEMBL3124390 | 0.74 | TAAR1 (0.42) | ACHEHTR2CHTR2AHTR2BNPC1 | |
| SCHEMBL3117055 | 0.74 | IDO1 (0.31) | — | |
| SCHEMBL7833417 | 0.74 | CYP3A4 (0.46) | KMT2AMEN1CYP19A1ALDH1A1MAPK1 | |
| SCHEMBL746723 | 0.74 | HTR2C (0.49) | ACHEHTR2CKMT2AMEN1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
| US-7863308-B2 | Substituted thiophenes | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100280086-A1 | SUBSTITUTED THIOPHENES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20080255036-A1 | Deuterated thiophene derivatives such as d2-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide; for modulating endothelin receptors; for treating, preventing, or ameliorating one or more symptoms of an endothelin-mediated disorder | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280086-A1 | SUBSTITUTED THIOPHENES | EDNRB, ECE1, EDNRA | ACHE 1045/4885HTR2C 168/4885KMT2A 4702/4885 |
| US-20080255036-A1 | Deuterated thiophene derivatives such as d2-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide; for modulating endothelin receptors; for treating, preventing, or ameliorating one or more symptoms of an endothelin-mediated disorder | EDNRA, EDNRB, TBXA2R | ACHE 3118/4885HTR2C 78/4885KMT2A 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.